Fulgent Genetics, Inc. (FLGT)

↓ Download CSV

CIK 0001674930 · Nasdaq · Services-Medical Laboratories

  • Sector Services
  • Incorporated DE
  • Fiscal year ends Dec 31

In fiscal 2025, Fulgent Genetics, Inc. reported revenue of $322.67M, up 13.8% from the prior year. The company ran a net loss, with a net margin of -18.8% and a gross margin of 40.6%. It held $1.21B in total assets against $106.81M in total liabilities.

Key ratios (FY2025)

40.6%
Gross margin
-28.2%
Operating margin
-18.8%
Net margin
-5.4%
Return on equity
+13.8%
Revenue growth (YoY)
Metric (FY)2025202420232022202120202019201820172016
Revenue$322.67M$283.47M$289.21M$618.97M$992.58M$421.71M$32.53M$21.35M$18.73M
Cost of Revenue$191.80M$176.25M$184.76M$252.07M$215.53M$89.81M$14.11M$10.70M$8.55M$6.72M
Gross Profit$130.88M$107.22M$104.46M$366.90M$777.05M$331.90M$18.42M$10.65M$10.18M$11.55M
Operating Income-$91.10M-$73.92M-$195.53M$178.53M$675.95M$290.16M-$428.0K-$5.07M-$3.48M$918.0K
Net Income-$60.51M-$42.71M-$167.82M$143.40M$507.36M$214.31M-$411.0K-$5.61M-$2.51M-$5.35M
Total Assets$1.21B$1.22B$1.24B$1.39B$1.28B$700.46M$88.76M$53.90M$57.18M$58.04M
Total Liabilities$106.81M$90.81M$102.04M$116.18M$112.84M$131.07M$5.98M$2.75M$3.01M$3.56M
Shareholders' Equity$1.11B$1.13B$1.14B$1.27B$1.16B$569.39M$82.78M$51.15M$54.18M$54.48M
Cash & Equivalents$50.19M$55.14M$97.47M$79.51M$164.89M$87.43M$11.96M$6.74M$6.49M$7.90M
Operating Cash Flow-$101.64M$21.06M$27.00M$253.52M$538.58M$140.63M$5.52M-$675.0K$1.33M$4.41M
Capital Expenditures$22.57M$40.31M$22.21M$18.77M$23.81M$35.13M$1.18M$2.32M$2.90M$3.79M
Shares Outstanding31.08M30.84M29.65M29.44M30.16M28.18M21.48M18.17M17.85M17.68M